Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring
Sponsor: Abbott Diabetes Care
Summary
This study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1/GIP) agonists.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
800
Start Date
2024-10-24
Completion Date
2027-12
Last Updated
2026-10-27
Healthy Volunteers
No
Conditions
Interventions
To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists
All subjects will then begin use of their prescribed GLP-1 or combination GIP/GLP-1 medication in accordance with the HCP's instructions. Subjects will be titrated to their maximum tolerable dose per the medication's approved titration schedule and according to their HCP's standard of care between Visits 2 and 3.
Locations (8)
Helios Clinical Research
Paradise Valley, Arizona, United States
East Coast Institute for Research, LLC
Jacksonville, Florida, United States
Excellence Medical and Research
Miami Gardens, Florida, United States
American Research Centers of Florida
Pembroke Pines, Florida, United States
Cross Creek Medical Clinic, PA
Fayetteville, North Carolina, United States
Medication Management
Greensboro, North Carolina, United States
M3 Wake Research, Inc
Dallas, Texas, United States
Care United Research
Forney, Texas, United States